Your session is about to expire
← Back to Search
Behavioral Intervention
Ads for Quitting Smoking
N/A
Waitlist Available
Led By Noel Brewer, PhD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be age 21 years or older
Be older than 18 years old
Must not have
Be younger than age 21 years
Not be able to read and speak English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after exposure to the ads, assessed during one-time online 15-minute survey.
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to find out which ads work best to help people who smoke menthol cigarettes quit smoking. Researchers will use an online study with around 1,400 US adults aged 21 and older
Who is the study for?
This trial is for US adults aged 21 or older who currently smoke menthol cigarettes. The goal is to find out which ads are most effective at encouraging them to quit smoking.
What is being tested?
The study is testing the effectiveness of different types of advertisements designed to help people quit smoking. Participants will be randomly assigned to view either control ads or intervention ads.
What are the potential side effects?
Since this trial involves viewing advertisements, there are no direct medical side effects associated with participation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 21 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am younger than 21 years old.
Select...
I cannot read or speak English.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after exposure to the ads, assessed during one-time online 15-minute survey.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after exposure to the ads, assessed during one-time online 15-minute survey.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Perceived message effectiveness for motivation
Secondary study objectives
Intentions to quit smoking
Perceived message effectiveness for response efficacy
Perceived message effectiveness for self-efficacy
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
5Treatment groups
Experimental Treatment
Group I: Ads about self-efficacy for quitting smokingExperimental Treatment1 Intervention
Participants will view ads designed to increase self-efficacy to quit smoking.
Group II: Ads about response efficacy for quitting smokingExperimental Treatment1 Intervention
Participants will view ads designed to increase response efficacy for quitting cigarettes.
Group III: Ads about readingExperimental Treatment1 Intervention
Participants will view non-smoking related ads on the benefits of reading.
Group IV: Ads about passwordsExperimental Treatment1 Intervention
Participants will view non-smoking related ads on passwords.
Group V: Ads about motivation to quit smokingExperimental Treatment1 Intervention
Participants will view ads designed to increase motivation to quit smoking.
Find a Location
Who is running the clinical trial?
University of North Carolina, Chapel HillLead Sponsor
1,569 Previous Clinical Trials
4,318,307 Total Patients Enrolled
5 Trials studying Smoking
2,325 Patients Enrolled for Smoking
Food and Drug Administration (FDA)FED
181 Previous Clinical Trials
1,547,249 Total Patients Enrolled
2 Trials studying Smoking
72 Patients Enrolled for Smoking
National Institute on Drug Abuse (NIDA)NIH
2,607 Previous Clinical Trials
3,328,415 Total Patients Enrolled
69 Trials studying Smoking
22,766 Patients Enrolled for Smoking
Noel Brewer, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
4 Previous Clinical Trials
4,911 Total Patients Enrolled
1 Trials studying Smoking
2,149 Patients Enrolled for Smoking
Marissa G Hall, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
6 Previous Clinical Trials
12,377 Total Patients Enrolled